The National Alzheimer’s Coordinating Center unites the collections of the neuropathology cores at 27 NIA-funded AD Research Centers into a single database. It contains records on 13,000 brains, 3,000 ...

PSEN1 encodes presenilin-1, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. More than 300 mutations in PSEN1 have been reported and mutations in PSEN1 are the most ...

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...

The port city of Lisbon, the launch point of many a voyage of exploration, seemed a fitting site to host the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related ...

At first blush, recent Phase 3 trial results from the anti-amyloid antibodies gantenerumab and lecanemab seem to be a study in opposites, one negative and one positive. At the 15th Clinical Trials on ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Species: Mouse Genes: SNCA Modification: SNCA: Transgenic Disease Relevance: Parkinson's Disease Strain Name: B6;DBA-Tg(Thy1-SNCA)61Ema Genetic Background: (C57BL/6 x DBA/2)F1 (strain of origin) ...

According to the latest study on tau-transgenic mice, methylene blue, a drug in clinical trials for frontotemporal dementia (FTD) and Alzheimer's disease (AD), stops decline in its tracks—but only ...

Early onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and ...

Lu AF87908 is a humanized mouse IgG1 monoclonal antibody to phosphorylated tau protein. It was generated by immunization of mice with a tau peptide spanning residues 386-408 and phosphorylated at ...

reactivity depends on both the N terminus (amino acids 7–9), and an amino acid sequence of tau (amino acids 313–322) in the third microtubule binding domain. Recognizes neurofibrillary tangles but ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...